Downregulation of VLA-4 on T cells as a marker of long term treatment response to interferon beta-1a in MS

J Neuroimmunol. 2005 Oct;167(1-2):175-82. doi: 10.1016/j.jneuroim.2005.06.022.

Abstract

We determined longitudinally the expression of a panel of adhesion molecules on T cells and soluble ICAM-1, VCAM-1 and tumor necrosis factor apoptosis inducing ligand (TRAIL) in serum during first year of the PRISMS Study with IFNbeta1a in MS. Clinical data and quantitative MRI data were available for 4 years. VLA-4 was down-regulated on T cells and VCAM-1 was up-regulated in serum during the first 3 to 6 months of therapy in patients with favorable long-term treatment response (EDSS progression </=1.0 in 4 years). Short disease duration and low EDSS were clinical pre-treatment characteristics related to good long-term response to therapy.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adjuvants, Immunologic / therapeutic use*
  • Adult
  • Apoptosis Regulatory Proteins / blood
  • Dose-Response Relationship, Drug
  • Down-Regulation / drug effects*
  • Female
  • Fluorescent Antibody Technique / methods
  • Humans
  • Integrin alpha4beta1 / metabolism*
  • Intercellular Adhesion Molecule-1 / blood
  • Interferon beta-1a
  • Interferon-beta / therapeutic use*
  • Longitudinal Studies
  • Male
  • Membrane Glycoproteins / blood
  • Middle Aged
  • Multiple Sclerosis / blood
  • Multiple Sclerosis / drug therapy*
  • T-Lymphocytes / drug effects*
  • TNF-Related Apoptosis-Inducing Ligand
  • Time Factors
  • Tumor Necrosis Factor-alpha

Substances

  • Adjuvants, Immunologic
  • Apoptosis Regulatory Proteins
  • Integrin alpha4beta1
  • Membrane Glycoproteins
  • TNF-Related Apoptosis-Inducing Ligand
  • TNFSF10 protein, human
  • Tumor Necrosis Factor-alpha
  • Intercellular Adhesion Molecule-1
  • Interferon-beta
  • Interferon beta-1a